ФАРМАКОГЕНЕТИЧЕСКИЕ АСПЕКТЫ РЕАЛИЗАЦИИ МЕТАБОЛИЧЕСКИХ НАРУШЕНИЙ ПРИ ИСПОЛЬЗОВАНИИ НЕЙРОЛЕПТИКОВ II ГЕНЕРАЦИИ

DOI: https://doi.org/None

Д.В. Иващенко (1), Р.Ф. Насырова (1), доктор медицинских наук, М.В. Иванов (1), доктор медицинских наук, профессор, А.Е. Тараскина (2), кандидат медицинских наук, Д.Н. Сосин (1), К.А. Сосина (1), С.Е. Хальчицкий (1), Д.А. Сычев (3), доктор медицинских наук, профессор, Н.Г. Незнанов (1), доктор медицинских наук, профессор 1 -Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева Минздрава России, Российская Федерация, 192019, Санкт-Петербург, ул. Бехтерева, д. 3; 2 -Первый Санкт-Петербургский государственный медицинский университет им. И.П. Павлова Минздрава России, Российская Федерация, 197022, Санкт-Петербург, ул. Льва Толстого, д. 6–8; 3 -Российская медицинская академия последипломного образования Минздрава России, Российская Федерация, 123995, Москва, ул. Баррикадная, д. 2/1 E-mail: [email protected]

Нейролептики – основные лекарственные препараты при лечении шизофрении. В последнее время очень широкое распространение получили нейролептики II генерации. Вместе с этим актуальной стала проблема метаболических нарушений как основного побочного эффекта этих препаратов. Благодаря растущей популярности фармакогенетики и персонализированной медицины получили развитие исследования ассоциации генетических полиморфизмов и выраженности побочных эффектов. В настоящем обзоре приведены результаты последних исследований изучений фармакодинамических генетических факторов, оказывающих влияние на метаболические расстройства при приеме нейролептиков. Рассмотрены медиаторные системы серотонина, дофамина, BDNF, лептина, гистамина, нейропептида Y, адреналина. Освещены маркеры для будущих исследований. Несмотря на достаточно обширную доказательную базу, ни один генетический маркер не считается пока применимым для реальной клинической практики.
Ключевые слова: 
нейролептики, метаболические расстройства, фармакогенетика, набор массы тела, маркеры
Для цитирования: 
Иващенко Д.В., Насырова Р.Ф., Иванов М.В., Тараскина А.Е., Сосин Д.Н., Сосина К.А., Хальчицкий С.Е., Сычев Д.А., Незнанов Н.Г. ФАРМАКОГЕНЕТИЧЕСКИЕ АСПЕКТЫ РЕАЛИЗАЦИИ МЕТАБОЛИЧЕСКИХ НАРУШЕНИЙ ПРИ ИСПОЛЬЗОВАНИИ НЕЙРОЛЕПТИКОВ II ГЕНЕРАЦИИ. Молекулярная медицина, 2015; (5): -
Список литературы: 
  1. Balt S.L., Galloway G.P., Baggott M.J., Schwartz Z., Mendelson J. Mechanisms and genetics of antipsychotic-associated weight gain. Clin Pharmacol. Ther. 2011; 90 (1): 179–83.
  2. Allison D.B., Mentore J.L., Heo M. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999; 156: 1686–96.
  3. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373: 31–41.
  4. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. Am. J. Psychiatry. 2006; 163 (4): 611–22.
  5. Farooqi S., O’Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006; 27 (7): 710–8. Epub 2006 Nov 22.
  6. Xu Y., Jones J.E., Kohno D., Williams K.W., Lee C.E., Choi M.J., Anderson J.G., Heisler L.K., Zigman J.M., Lowell B.B., Elmquist J.K. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron. 2008; 60 (4): 582–9.
  7. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., Jayathilake K., Meltzer H.Y., Roth B.L. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003; 28; 519–26.
  8. Perez-Iglesias R., Vazquez-Barquero J.L., Amado J.A., Berja A., Garcia-Unzueta M.T., Pelayo-Terán J.M., Carrasco-Marín E., Mata I., Crespo-Facorro B. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J. Clin. Psychopharmacol. 2008; 28; 289–95.
  9. Minet-Ringuet J., Even P.C., Valet P., Carpéné C., Visentin V., Prévot D., Daviaud D., Quignard-Boulange A., Tomé D., de Beaurepaire R. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry. 2007; 12 (6): 562–71.
  10. Pavan C., Vindigni V., Michelotto L., Rimessi A., Abatangelo G., Cortivo R., Pinton P., Zavan B. Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β. Pharmacogenomics J. 2010; 10 (5): 408–17.
  11. Горобец Л.Н., Буланов В.С., Василенко Л.М., Литвинов А.В., Иванова Г.П., Поляковская Т.П. Нейролептические метаболические нарушения при лечении антипсихотическими средствами нового поколения. Журн. неврологии и психиатрии им. С.С. Корсакова. 2014; 2: 59–68. [Gorobec L.N., Bulanov V.S., Vasilenko L.M., Litvinov A.V., Ivanova G.P., Poljakovskaja T.P. Neuroleptic metabolic dysfunctions in patients treated with new generation antipsychotics. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2014; 2: 59–68 (in Russian)]
  12. Буланов В.С., Василенко Л.М. Метаболические расстройства, связанные с терапией оланзапином, и методы их коррекции. Обзоры по клинической фармакологии и лекарственной терапии. 2010; 8: 1: 33. [Bulanov V.S., Vasilenko L.M. Metabolic disorders linked with Olanzapin and methods of correction. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii. 2010; 8: 1: 33 (in Russian)]
  13. Горобец Л.Н., Ермолаева Л.Г., Жмурина М.В. Проблемы увеличения веса и развития сахарного диабета при нейролептической терапии шизофрении. Сборник «Метаболические побочные эффекты и осложнения при пcихофармакотерапии». Под ред. И.Я. Гуровича и А.Б. Шмуклера. Социальная и клиническая психиатрия (Приложение). 2003; 22–8. [Gorobec L.N., Ermolaeva L.G., Zhmurina M.V. Problems of the weight gain and diabetes mellitus during the antipsychotics therapy of schizophrenia. Abstract book «Metabolicheskie pobochnye jeffekty i oslozhnenija pri pcihofarmakoterapii» Editorial board: I.Ja. Gurovich and A.B. Shmukler. Social and clinical psychiatry (Suppl.). 2003; 22–8 (in Russian)]
  14. Wang Y.C., Bai Y.M., Chen J.Y., Lin C.C., Lai I.C., Liou Y.J. Polymorphism of the adrenergic receptor A2a-1291C>G genetic variation and clozapine-induced weight gain. J. Neural Transm. 2005; 112, 1463–8.
  15. Park Y.M., Chung Y.C., Lee S.H., Lee K.J., Kim H., Byun Y.C., Lim S.W., Paik J.W., Lee H.J. Weight gain associated with the a2a-adrenergic receptor 1291C/G polymorphism and olanzapine treatment. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2006; 141B, 394–7.
  16. Sickert L., Müller D.J., Tiwari A.K., Shaikh S., Zai C., De Souza R., De Luca V., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Association of the a2A adrenergic receptor-1291 C/G polymorphism and antipsychotic-induced weight gain in European–Americans. Pharmacogenomics. 2009; 10, 1169–76.
  17. De Luca V., Souza R.P., Viggiano E., Sickert L., Teo C., Zai C., Tiwari A.K., Müller D.J., Lieberman J.A., Volavka J., Meltzer H.Y., Kennedy J.L. Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. Hum. Psychopharmacol. 2011; 26 (6): 386–91.
  18. Risselada A.J., Vehof J., Bruggeman R., Wilffert B., Cohen D., Al Hadithy A.F., Arends J., Mulder H. Association between the 1291-C/G polymorphism in the adrenergic α-2a receptor and the metabolic syndrome. J. Clin. Psychopharmacol. 2010; 30 (6): 667–71.
  19. Ujike H., Nomura A., Morita Y., Morio A., Okahisa Y., Kotaka T., Kodama M., Ishihara T., Kuroda S. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J. Clin. Psychiatry. 2008; 69 (9): 1416–22.
  20. Tsai S.J., Yu Y.W., Lin C.H., Wang Y.C., Chen J.Y., Hong C.J. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology. 2004; 50 (1): 37–40.
  21. Tsai A., Liou Y.J., Hong C.J., Wu C.L., Tsai S.J., Bai Y.M. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotictreatment. Neuromolecular Med. 2011; 13 (4): 328–33.
  22. Zhang X.Y., Zhou D.F., Wu G.Y., Cao L.Y., Tan Y.L., Haile C.N., Li J., Lu L., Kosten T.A., Kosten T.R. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology. 2008; 33: 2200–5.
  23. Thorleifsson G., Walters G.B., Gudbjartsson D.F., Steinthorsdottir V., Sulem P., Helgadottir A., Styrkarsdottir U., Gretarsdottir S., Thorlacius S., Jonsdottir I., Jonsdottir T., Olafsdottir E.J., Olafsdottir G.H., Jonsson T., Jonsson F., Borch-Johnsen K., Hansen T., Andersen G., Jorgensen T., Lauritzen T., Aben K.K., Verbeek A.L., Roeleveld N., Kampman E., Yanek L.R., Becker L.C., Tryggvadottir L., Rafnar T, Becker D.M., Gulcher J., Kiemeney L.A., Pedersen O., Kong A., Thorsteinsdottir U., Stefansson K. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat. Genet. 2009; 41 (1): 18–24.
  24. Hong C.J., Liou Y.J., Bai Y.M., Chen T.T., Wang Y.C., Tsai S.J. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010; 20 (6): 359–66.
  25. Houston J.P., Kohler J., Bishop J.R., Ellingrod V.L., Ostbye K.M., Zhao F., Conley R.R., Poole Hoffmann V., Fijal B.A. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J. Clin. Psychiatry. 2012; 73 (8): 1077–86.
  26. Lencz T., Robinson D.G., Napolitano B., Sevy S., Kane J.M., Goldman D., Malhotra A.K. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010; 20 (9): 569–72.
  27. Müller D.J., Zai C.C., Sicard M., Remington E., Souza R.P., Tiwari A.K., Hwang R., Likhodi O., Shaikh S., Freeman N., Arenovich T., Heinz A., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2012; 12 (2): 156–64.
  28. Popp J., Leucht S., Heres S., Steimer W. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J. 2009; 9 (1): 71–7.
  29. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., Marder S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry. 1999; 60: 358–63.
  30. Hong C.J., Lin C.H., Yu Y.W., Chang S.C., Wang S.Y., Tsai S.J. Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr. Genet. 2002; 12 (3): 169–71.
  31. Godlewska B.R., Olajossy-Hilkesberger L., Olajossy M., Limon J., Landowski J. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain. J. Clin. Psychopharmacol. 2013; 33 (3): 436–7.
  32. Wu R., Zhao J., Shao P., Ou J., Chang M. Genetic predictors of antipsychotic-induced weight gain: a case-matched multi-gene study. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011; 36 (8): 720–3.
  33. Vehof J., Risselada A.J., Al Hadithy A.F., Burger H., Snieder H., Wilffert B., Arends J., Wunderink L., Knegtering H., Wiersma D., Cohen D., Mulder H., Bruggeman R. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl.). 2011; 216 (2): 257–65.
  34. Souza R.P., Tiwari A.K., Chowdhury N.I., Ceddia R.B., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Müller D.J. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J. Psychiatr. Res. 2012; 46 (4): 462–8.
  35. Ellingrod V.L., Perry P.J., Ringold J.C., Lund B.C., Bever-Stille K., Fleming F., Holman T.L., Miller D. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am. J. Med. Genet B. Neuropsychiatr. Genet. 2005; 134B (1): 76–8.
  36. Ryu S., Cho E.Y., Park T., Oh S., Jang W.S., Kim S.K., Lee D., Hong K.S. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007; 31 (3): 673–7.
  37. Thompson A., Lavedan C., Volpi S. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res. 2010; 175 (3): 271–3.
  38. De Luca V., Mueller D.J., de Bartolomeis A., Kennedy J.L. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int. J. Neuropsychopharmacol. 2007; 10 (5): 697–704.
  39. Sicard M.N., Zai C.C., Tiwari A.K., Souza R.P., Meltzer H.Y., Lieberman J.A., Kennedy J.L., Müller D.J. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010; 11 (11): 1561–71.
  40. Gunes A., Melkersson K.I., Scordo M.G., Dahl M.L. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J. Clin. Psychopharmacol. 2009; 29 (1): 65–8.
  41. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Cao L.Y., Xu Q., Shen Y., Kosten T.A., Kosten T.R. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J. Clin. Psychopharmacol. 2007; 27 (3): 246–51.
  42. Gregoor J.G., van der Weide J., Loovers H.M., van Megen H.J., Egberts T.C., Heerdink E.R. Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics. 2011; 12 (6): 919–23.
  43. Templeman L.A., Reynolds G.P., Arranz B., San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005; 15 (4): 195–200.
  44. Brandl E.J., Frydrychowicz C., Tiwari A.K., Lett T.A., Kitzrow W., Büttner S., Ehrlich S., Meltzer H.Y., Lieberman J.A., Kennedy J.L., Müller D.J., Puls I. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012; 38 (2): 134–41.
  45. Opgen-Rhein C., Brandl E.J., Müller D.J., Neuhaus A.H., Tiwari A.K., Sander T., Dettling M. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics. 2010; 11 (6): 773–80.
  46. Perez-Iglesias R., Mata I., Amado J.A., Berja A., Garcia-Unzueta M.T., Martínez García O., Arranz M.J., Vazquez-Barquero J.L., Crespo-Facorro B. Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J. Clin. Psychopharmacol. 2010; 30 (6): 661–6.
  47. Yevtushenko O.O., Cooper S.J., O’Neill R., Doherty J.K., Woodside J.V., Reynolds G.P. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br. J. Psychiatry. 2008; 192 (6): 424–8.
  48. Ellingrod V.L., Bishop J.R., Moline J., Lin Y.C., Miller D.D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol. Bull. 2007; 40 (1): 57–62.
  49. Ruaño G., Goethe J.W., Caley C., Woolley S., Holford T.R., Kocherla M., Windemuth A., de Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry. 2007; 12 (5): 474–82.
  50. Yanik T., Kursungoz C., Sutcigil L., Ak M. Weight gain in risperidone therapy: investigation of peripheral hypothalamic neurohormone levels in psychotic patients. J. Clin. Psychopharmacol. 2013; 33 (5): 608–13.
  51. Tiwari A.K., Brandl E.J., Weber C., Likhodi O., Zai C.C., Hahn M.K., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Müller D.J. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J. Clin. Psychopharmacol. 2013; 33 (1): 11–7.
  52. Zhang Q., Deng C., Huang X.F. The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Psychoneuroendocrinology. 2013; 38 (11): 2423–38.
  53. Smith R.C., Rachakonda S., Dwivedi S., Davis J.M. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. Psychiatry Res. 2012; 199 (3): 159–63.
  54. Tiwari A.K., Zai C.C., Likhodi O., Lisker A., Singh D., Souza R.P., Batra P., Zaidi S.H., Chen S., Liu F., Puls I., Meltzer H.Y., Lieberman J.A., Kennedy J.L., Müller D.J. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology. 2010; 35 (6): 1315–24.
  55. Nurmi E.L., Spilman S.L., Whelan F., Scahill L.L., Aman M.G., McDougle C.J., Arnold L.E., Handen B., Johnson C., Sukhodolsky D.G., Posey D.J., Lecavalier L., Stigler K.A., Ritz L., Tierney E., Vitiello B., McCracken J.T. Research Units on Pediatric Psychopharmacology Autism Network. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl. Psychiatry. 2013; 3: e274.
  56. Monteleone P., Milano W., Petrella C., Canestrelli B., Maj M. Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain. J. Clin. Psychopharmacol. 2010; 30 (4): 441–5.
  57. Graff M., Ngwa J.S., Workalemahu T., Homuth G., Schipf S., Teumer A., Völzke H., Wallaschofski H., Abecasis G.R., Edward L., Francesco C., Sanna S., Scheet P., Schlessinger D., Sidore C., Xiao X., Wang Z., Chanock S.J., Jacobs K.B., Hayes R.B., Hu F., Van Dam R.M.; GIANT Consortium, Crout R.J., Marazita M.L., Shaffer J.R., Atwood L.D., Fox C.S., Heard-Costa N.L., White C., Choh A.C., Czerwinski S.A., Demerath E.W., Dyer T.D., Towne B., Amin N., Oostra B.A., Van Duijn C.M., Zillikens M.C., Esko T., Nelis M., Nikopensius T., Metspalu A., Strachan D.P., Monda K., Qi L., North K.E., Cupples L.A., Gordon-Larsen P., Berndt S.I. Genome-wide analysis of BMI in adolescents and young adults reveals additional insight into the effects of genetic loci over the life course. Hum. Mol. Genet. 2013; 22 (17): 3597–607.
  58. Malhotra A.K., Correll C.U., Chowdhury N.I., Müller D.J., Gregersen P.K., Lee A.T., Tiwari A.K., Kane J.M., Fleischhacker W.W., Kahn R.S., Ophoff R.A., Meltzer H.Y., Lencz T., Kennedy J.L. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatry. 2012; 69 (9): 904–12.
  59. Czerwensky F., Leucht S., Steimer W. MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int. J. Neuropsychopharmacol. 2013; 16 (9): 2103–9.
  60. Teutsch S.M., Bradley L.A., Palomaki G.E., Haddow J.E., Piper M., Calonge N., Dotson W.D., Douglas M.P., Berg A.O. EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009; 11 (1): 3–14.